BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/24/2022 9:40:42 AM | Browse: 360 | Download: 683
 |
Received |
|
2021-08-22 16:07 |
|
Peer-Review Started |
|
2021-08-22 16:09 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-11-11 09:16 |
|
Revised |
|
2021-11-23 16:02 |
|
Second Decision |
|
2022-02-17 05:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-02-20 13:20 |
|
Articles in Press |
|
2022-02-20 13:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-02-15 00:22 |
|
Typeset the Manuscript |
|
2022-03-14 00:47 |
|
Publish the Manuscript Online |
|
2022-03-24 09:40 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Immunotherapy in triple-negative breast cancer: A literature review and new advances
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Rossana Ruiz, Hugo Fuentes, Carlos A Castaneda, Tatiana Vidaurre, Silvia Neciosup and Henry L Gomez |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Guillermo Arturo Valencia, MD, Medical Assistant, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Avenue 2520, Surquillo, Lima 15000, Peru. guillermo.valencia.mesias@gmail.com |
| Key Words |
Triple-negative breast cancer; Early disease; Metastatic disease; Immunotherapy; Biomarkers |
| Core Tip |
Triple-negative breast cancer (TNBC) is an exceptionally heterogeneous disease and historically a cancer with limited treatment options other than chemotherapy. Recent advances in immunotherapy has changed the standard of care in selected groups, especially in metastatic TNBC. This article review continues the detailed, updated and comprehensive literature review regarding immunotherapy in TNBC, including the discussion of clinical trials in different scenarios (metastatic, neoadjuvant, adjuvant) and potential biomarkers to provide useful knowledge for medical oncologists and the medical community. Our goal is sharing updated information for TNBC which is considered an overlooked population with an enormous necessity of novel treatments and biomarkers. |
| Publish Date |
2022-03-24 09:40 |
| Citation |
Valencia GA, Rioja P, Morante Z, Ruiz R, Fuentes H, Castaneda CA, Vidaurre T, Neciosup S, Gomez HL. Immunotherapy in triple-negative breast cancer: A literature review and new advances. World J Clin Oncol 2022; 13(3): 219-236 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i3/219.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i3.219 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
